SCHEMBL1467686

SCHEMBL1467686

Cc1c(Cc2scnc2S(=O)(=O)c2ccccc2)c2cc(F)ccc2n1CC(=O)O

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 20/20 0.73
PTGDR Q13258 2/20 0.56
PTGIR P43119 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1465689 0.91 PTGDR2 (0.61) PTGDR2PTGDRPTGIR
SCHEMBL1467633 0.89 PTGDR2 (0.64) PTGDR2PTGDRPTGIR
SCHEMBL3716360 0.89 PTGDR2 (0.59) PTGDR2
SCHEMBL1466111 0.87 PTGDR2 (0.71) PTGDR2PTGDRPTGIR
SCHEMBL3714818 0.87 PTGDR2 (0.68) PTGDR2PTGDRPTGIR
SCHEMBL1466340 0.85 PTGDR2 (0.73) PTGDR2PTGDRPTGIR
SCHEMBL3719021 0.84 PTGDR2 (0.67) PTGDR2PTGDRPTGIR
SCHEMBL1466910 0.84 PTGDR2 (1.00) PTGDR2PTGDRPTGIR
SCHEMBL3723717 0.84 PTGDR2 (0.72) PTGDR2PTGDRPTGIR
SCHEMBL3717849 0.84 PTGDR2 (0.66) PTGDR2PTGDRPTGIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225617-A1 INDOLES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-08-29 US disclosed
US-20130225617-A1 INDOLES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-08-29 US disclosed
US-20130225617-A1 INDOLES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-08-29 US disclosed
US-8394836-B2 Indoles and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-03-12 US disclosed
US-8394836-B2 Indoles and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-03-12 US disclosed
US-8394836-B2 Indoles and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-03-12 US disclosed
EP-2327693-B9 Indoles and their therapeutic use PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-10-24 EP disclosed
EP-2327693-B1 Indoles and their therapeutic use PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-06-20 EP disclosed
EP-2327693-A1 Indoles and their therapeutic use Pulmagen Therapeutics (Asthma) Limited (GB) 2011-06-01 EP disclosed
US-20110071175-A1 Indoles and Their Therapeutic Use GB005, INC. 2011-03-24 US disclosed
US-20110071175-A1 Indoles and Their Therapeutic Use GB005, INC. 2011-03-24 US disclosed
US-20110071175-A1 Indoles and Their Therapeutic Use GB005, INC. 2011-03-24 US disclosed
WO-2009077728-A1 INDOLES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225617-A1 INDOLES AND THEIR THERAPEUTIC USE IDO2, IDO1, RORB PTGDR2 39/4885PTGDR 60/4885PTGIR 183/4885
US-20110071175-A1 Indoles and Their Therapeutic Use FPR3, HRH2, HRH4 PTGDR2 161/4885PTGDR 139/4885PTGIR 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.